On March 20, 2026, Novo Nordisks Indian patent on semaglutide expired. Within 48 hours, over 15 generic versions launched from Sun Pharma, Dr. Reddys, Natco, Zydus, Alkem, Glenmark, and others. As of April 2026, more than 40 DCGI approved generic semaglutide brands are in circulation. Prices have crashed by up to 90 percent compared to branded Ozempic.
This guide breaks down every major brand, its format, its approved indications, and what patients and prescribing physicians need to know. All prices are indicative April 2026 MRP and vary by city and pharmacy.
What changed on March 20, 2026
Before the patent expiry, Novo Nordisks branded Ozempic cost between Rs. 8,800 and Rs. 11,175 per month in India. Wegovy for weight management was priced at Rs. 10,850 to Rs. 16,400 per month. These prices made semaglutide effectively inaccessible to most Indian middle class households.
Within 48 hours of the patent lapse, Indian manufacturers began launching their own versions. The cheapest generic now available, Natco Pharmas Semanat in multi dose vial format, costs approximately Rs. 1,290 per month at the 0.25 mg starter dose. That is a 90 percent reduction for the identical active molecule, manufactured under CDSCO pharmacopoeial standards, with Phase 3 Indian clinical trial data on file.
Novo Nordisk responded on March 31, 2026 by cutting branded Ozempic and Wegovy prices by 24 to 27 percent. The 0.25 mg Ozempic dose now costs Rs. 1,415, and the 1 mg dose costs Rs. 2,275. This is still significantly higher than generic alternatives but closer than before.
Major generic brands in India
Not all generic semaglutide is packaged the same way. Some brands sell in multi dose vials which are cheapest but require trained dose loading. Others come in prefilled disposable pens which are more convenient but cost 30 to 50 percent more. A third category uses reusable multi dose pens with refillable cartridges.
Natco Pharma: Semanat and Semafull
Natco was among the first Indian companies to receive CDSCO approval in February 2026. Semanat is the multi dose vial format for Type 2 diabetes, priced at Rs. 1,290 to Rs. 1,750 per month depending on dose. Semafull is approved for both diabetes and chronic weight management. A pen device launch was planned for April 2026 at Rs. 4,000 to Rs. 4,500 per month.
Dr. Reddys: Obeda
Dr. Reddys was the first Indian company to receive DCGI approval and launched Obeda as a prefilled disposable pen designed for once weekly subcutaneous administration. Available in 2 mg and 4 mg cartridge strengths. Monthly cost approximately Rs. 4,200. Obeda is co marketed by USV under the brand name Usema.
Sun Pharma: Noveltreat and Sematrinity
Sun Pharma, one of Indias largest generics manufacturers, launched two brands. Noveltreat is indicated for chronic weight management and is available in five dose strengths from 0.25 mg to 2.4 mg. Sematrinity is indicated for Type 2 diabetes. Both come in prefilled pen format. Starting price Rs. 3,400 per month.
Zydus: Semaglyn, Mashema, Alterme
Zydus launched three brand names covering different indications. All three share a reusable multi dose pen with a 15 mg in 3 ml cartridge that allows dose titration. Monthly cost approximately Rs. 2,200. Zydus also has a co marketing arrangement with Lupin, who markets the same molecule under Semanext and Livarise.
Alkem Laboratories: Semasize, Obesema, Hepaglide
Alkem offers the lowest priced prefilled pen at Rs. 1,800 per month. Semasize is for Type 2 diabetes, Obesema for chronic weight management, and Hepaglide is the only brand specifically targeting the emerging metabolic dysfunction associated steatohepatitis indication. A reusable pen option is also available.
Glenmark: GLIPIQ
Glenmark GLIPIQ is available in both vial and prefilled pen formulations. Vial format enables lowest cost flexible dosing. Glenmarks Sankalp patient support programme provides injection training and telephone support.
Eris Lifesciences: Sundae
Eris partnered with Natco to commercialize semaglutide. Brand Sundae is available in multi dose vial at Rs. 220 per shot, making it the lowest entry price of any semaglutide product in India. The vial format is suited to hospital and clinic settings where nurses administer doses.
Mankind Pharma: Samakind
Mankind is the only Indian company to launch oral semaglutide, a generic equivalent of Rybelsus, in all three dosages. Mankinds key advantage is its Tier 2 and Tier 3 city distribution, which is deeper than any other Indian pharma company. Samakind may be the first semaglutide brand to meaningfully reach patients outside metro India.
Which format should you choose?
In my pharmacology practice, the decision is not purely about price. Three factors matter most.
Ability to self administer
For a patient who has never injected before, prefilled pens are worth the 30 to 50 percent premium. Dose errors with vials, especially at the 0.25 mg starter dose, are a real risk. Even a small overdose can cause severe nausea and vomiting for a week. A pen with a fixed dose dial eliminates this risk.
Long term affordability
Semaglutide for obesity is typically a 12 to 24 month commitment. For diabetes, many patients continue indefinitely. The price difference between vial at Rs. 1,290 per month and pen at Rs. 1,800 to Rs. 2,200 per month adds up to Rs. 10,000 to Rs. 20,000 over 24 months. That is significant for middle income households.
Storage and travel
Prefilled pens are more forgiving with storage. Vials need careful refrigeration. Pens can tolerate up to 28 days at room temperature below 30 degrees Celsius once opened. For patients who travel frequently or work in environments without reliable refrigeration, pens are the safer choice.
Safety and clinical backing
All Indian generics passed CDSCO bioequivalence testing plus Phase 3 Indian clinical trial data before launch. Indias DCGI requires Indian manufacturers to submit Phase 3 data from Indian patients before approval, which is a stricter standard than the simple bioequivalence pathway used in the United States for most generics.
However, bioequivalent does not mean identical clinical outcomes. The pivotal trials behind semaglutide (STEP and SUSTAIN series) were run on Novos branded product. Real world data from Indian generics is still limited in April 2026, though early outcomes look consistent with expectations.
For patients starting generic semaglutide, I recommend the following monitoring protocol:
- Baseline HbA1c, fasting glucose, and lipid profile before starting
- Repeat HbA1c at 12 weeks to confirm therapeutic response
- Monitor closely for GI side effects in weeks 1 to 2, which are common regardless of brand
- Do not switch between brands mid cycle unless medically necessary
- Report any persistent severe nausea, vomiting, or upper abdominal pain to prescribing physician
Who should not take semaglutide
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should be used with caution in pancreatitis history, severe gastroparesis, severe renal impairment, and during pregnancy or breastfeeding. Pediatric use in patients under 12 years is not established.
The regulatory context
Semaglutide is classified as Schedule H in India. It cannot be purchased over the counter. Prescription must come from an endocrinologist or internal medicine specialist. Cardiologists may prescribe for cardiovascular risk indications. Retail pharmacy sales require the prescription to be on file.
Counterfeit products are a real concern given the price differential. Always purchase from licensed pharmacies, verify CDSCO approval codes on packaging, and avoid online sources without verified credentials.
My prescribing preference in April 2026
For most patients starting semaglutide in April 2026, I recommend a prefilled pen from a major manufacturer, such as Alkem Semasize at Rs. 1,800, Zydus Semaglyn at Rs. 2,200, or Sun Pharma Noveltreat at Rs. 3,400 depending on affordability. The ease of use improves adherence, and adherence is what determines whether the drug works. Saving Rs. 500 per month on a vial but missing doses because of injection confusion is a false economy.
For cost sensitive patients with clinician support for injections, Natco Semanat vial at Rs. 1,290 per month is the most affordable option globally. It requires a trained individual to load each dose but is pharmacologically identical to the prefilled pen alternatives.
Whichever brand you choose, never start semaglutide without an endocrinologist or trained physician supervision. This is a powerful drug with real side effects, and cheap should never mean self prescribed.